Keywords: xolair, inflammation, compound, omalizumab, first, anti-ige, antibody

Xolair "inflammation compound of the year"

Article | 11 October 2004

Print This

Xolair (omalizumab), the first anti-IgE antibody to be approved by the US Food and Drug Administration, has been named the 2004 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in